Amarin Corporation (AMRN) investor relations material

Executive summary

• Focused on expanding access and adoption of VASCEPA® through a partner-based international model and restructuring to strengthen financials, resulting in $70 million in annual cost savings and positive cash flow in Q4 2025.

• Ended 2025 with $303 million in cash and no debt, positioning for cost-efficient revenue generation in the U.S. and globally.

• Key 2025 milestones included the Recordati licensing agreement for European commercialization, streamlining operations, and maintaining U.S. market leadership.

Voting matters and shareholder proposals

• Shareholders will vote on re-election of seven directors, advisory approval of executive compensation, auditor appointment, share issuance authority, stock incentive plan amendment, disapplication of pre-emption rights, and electronic delivery of proxy materials.

• Proposals 12 and 13 require at least 75% approval and focus on cost-saving measures: equity compensation for non-employee directors and electronic proxy delivery.

• Board recommends voting FOR all proposals and director nominees.

Board of directors and corporate governance

• Board consists of a majority of independent directors, with all key committees chaired by independents.

• Board committees include Audit, Remuneration, and Nominating and Corporate Governance, all comprised of independent directors.

• Board leadership structure separates the roles of Chairman and CEO, with regular meetings of independent directors.

• Code of Conduct and Stock Ownership Guidelines in place for directors and executives.